Table 4.
Delafloxacin and quinolone comparators MIC frequency distributions for the most frequent ABSSSI isolates.
| N° (cumulative %) of isolates inhibited at MIC (mg/L) of: |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Microorganism or Microorganism group/ Antimicrobial agent | ≤ 0.008 | 0.016 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | ≥ 4 | n (R%) |
| S. aureus (n=18) | |||||||||||
| Delafloxacina | 11 (61.1 %) | 1 (66.7 %) | 0 | 1 (72.2 %) | 1 (77.8 %) | 1 (83.3 %) | 0 | 0 | 2 (94.4) | 1 (100 %) | 3 (16.6) |
| Levofloxacin | 0 | 0 | 0 | 0 | 1 (5.6 %) | 0 | 12 (72.2 %) | 0 | 0 | 5 (100 %) | 5 (27.8) |
| Ciprofloxacin | 1 (5.6 %) | 0 | 0 | 0 | 0 | 0 | 3 (22.2 %) | 9 (72.2 %) | 0 | 5 (100 %) | 5 (27.8) |
| Staphylococcus Coagulase Negative (n=18) | |||||||||||
| Delafloxacina | 6 (33.3 %) | 1 (38.9 %) | 1 (44.5 %) | 2 (55.7 %) | 2 (66.9 %) | 3 (83.7 %) | 1 (89.3 %) | 1 (94.9 %) | 0 | 1 (100 %) | 2 (11.1) |
| Levofloxacin | 0 | 0 | 0 | 0 | 0 | 2 (11.1 %) | 6 (44.4 %) | 0 | 0 | 10 (100 %) | 10 (55.6) |
| Ciprofloxacin | 0 | 0 | 0 | 0 | 1 (5.6 %) | 5 (33.3 %) | 0 | 1 (38.9 %) | 0 | 11 (100 %) | 11 (61.1) |
| Enterobacter cloacae (n=7) | |||||||||||
| Delafloxacinb | 2 (28.6 %) | 1 (42.9 %) | 2 (7.,4 %) | 0 | 0 | 0 | 1 (85.7 %) | 1 (100 %) | 0 | 0 | 1 (14.3) |
| Levofloxacin | 2 (28.6 %) | 1 (42.9 %) | 3 (85.7 %) | 1 (100 %) | 0 | 0 | 0 | 0 | 0 | ||
| Ciprofloxacin | 3 (42.9 %) | 0 | 1 (57.1 %) | 2 (85.7 %) | 0 | 0 | 1 (100 %) | 0 | 0 | 0 | 0 |
| Pseudomonas spp. (n=16) | |||||||||||
| Delafloxacinb | 1 (6.3 %) | 3 (25.0 %) | 2 (37.5 %) | 1 (43.8 %) | 5 (75.0 %) | 1 (81.3 %) | 2 93.8 %) | 0 | 1 (100 %) | 1 (6.2) | |
| Levofloxacin | 0 | 0 | 1 (6.3 %) | 1 (12.5 %) | 0 | 4 (37.5 %) | 2 (50.0 %) | 0 | 4 (75.0 %) | 4 (100 %) | 8 (50.0) |
| Ciprofloxacin | 0 | 2 (12.5 %) | 0 | 3 (31.3 %) | 0 | 1 (37.5 %) | 0 | 2 (50.0 %) | 2 (62.5 %) | 6 (100 %) | 10 (62.5) |
| Klebsiella spp. (n=10) | |||||||||||
| Delafloxacinb | 1 (10.0 %) | 0 | 0 | 1 (20.0 %) | 0 | 1 (30.0 %) | 0 | 3 (60.0 %) | 2 (80.0 %) | 2 (100 %) | 7 (70.0) |
| Levofloxacin | 1 (10.0 %) | 0 | 0 | 0 | 0 | 1 (20.0 %) | 0 | 1 (30.0 %) | 2 (50.0 %) | 5 (100 %) | 7 (70.0) |
| Ciprofloxacin | 1 (10.0 %) | 0 | 0 | 0 | 0 | 0 | 1 (20.0 %) | 0 | 0 | 8 (100 %) | 8 (80.0) |
Shaded cells indicate the breakpoints for each antimicrobial agent according to BRCAST/EUCAST (2021) or FDA (2020).
a
All CoNS were classified for delafloxacin according to the breakpoint for S. haemolyticus, preconized by the FDA (2020).
b
Delafloxacin breakpoints used are from FDA (2020) and for the other quinolone comparators breakpoints are from BRCAST/EUCAST (2021).